ArticleBMC cancer2024

Bevacizumab as a mitigating factor for the impact of high systemic immune-inflammation index on chemorefractory in advanced epithelial ovarian cancer.

Yan-Ping Fu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.